RAC1 and prostate carcinoma: In addition, ERK activity was not affected by Rac1 inhibition in lymphoma cells further suggesting that this Rac1 targeting strategy exerts its effect via modulation of the PAK1-AKT signaling pathway, but not the MAP kinases, to affect prostate cancer cell proliferation [66].